About
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company based in Aliso Viejo, California. Founded in 1998, it focuses on developing innovative therapies for chronic eye diseases, including glaucoma, corneal disorders, and retinal diseases. The company is known for pioneering micro-invasive glaucoma surgery (MIGS) with its iStent technology, the first FDA-approved MIGS device in the U.S. This technology offers a less invasive surgical option to help reduce intraocular pressure. Glaukos has expanded its product range to include advanced MIGS devices like the iStent inject W and iStent infinite, as well as sustained-release drug delivery implants such as the iDose TR. The company has also acquired DOSE Medical and Avedro to enhance its offerings in sustained pharmaceutical therapies and corneal health. With products approved in over 30 countries, Glaukos serves ophthalmologists, eye surgeons, and healthcare providers, aiming to improve patient outcomes and quality of life through effective and less invasive treatment options.
Technologies
Keywords
Company Information
-
Employees 1000
-
Founded 1998
-
Annual Revenue $383481000
-
Total Funding $290693573
Location
26600 Aliso Viejo Pkwy, Aliso Viejo, California, United States, 92656-2616
